Moderna Inc said on Thursday its COVID-19 shot was about 93% effective through six months after the second dose, showing hardly any change from the 94% efficacy reported in its original clinical trial.
That compares favorably to data from Pfizer Inc and BioNTech SE last week in which they said their vaccine’s efficacy waned around 6% every two months, declining to around 84% six months after the second shot.
Both the Moderna and Pfizer-BioNTech vaccines are based on messenger RNA (mRNA) technology.
“Our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant,” Moderna Chief Executive Stéphane Bancel said.
However, a booster dose will be necessary prior to the winter season as antibody levels are likely to wane, Moderna said.